ZURA

Over the past six months, Zura Bio reported its First Quarter and Full Year financial results, including a net loss for the quarter and advancements in its Phase 2 studies. They also announced inducement grants, participation in investor conferences, and the closing of a $144 million public offering. The stock price has fluctuated, with a recent decrease but a significant gain over the past 12 months. The public offering in February 2026 generated gross proceeds of approximately $144 million, strengthening the company's balance sheet and extending its cash runway through at least the end of 2028.